Septic Shock Clinical Trial
Official title:
Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults
During Infection, oflfending microbes interact with the host immune system producing a
downstream inflammatory cascade involving cytokines and other mediators, which in turn
triggers a systemic response. The resultant effects linclude vasodilation, increased vascular
permeability, myocardial depression, and impairment of the coagulation cascade, resulting in
global imbalance of systemic oxygen supply and demand. During the late stage of sepsis,
immunosuppression predominates, leading to multi-organ dysfunction and further clinical
deterioration .
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host
response to infection with two or three on Quick Sepsis-related organ failure assessment
score (qSOFA). Septic shock is defined as the presence of sepsis and refractory hypotension
to fluid management. Vasopressors are needed to maintain systolic blood pressure more than
90mmHg or mean blood pressure more than 65 mmHg .
Experimental and Clinical evidence suggests that sepsis is associated with dysregulated
response of Hypothalamic-pituitary-adrenal axis that may involve any of the steps from
cortisol production to cortisol use by cells .
Glucocorticoid therapy for the treatment of septic shock remains controversial, with
conflicting evidence regarding a mortality benefit. It has been used in patients with septic
shock who remained hypotensive after fluid and vasopressor resuscitation.
Fludrocortisone is a corticosteroid and acts as a powerful mineralocorticoid along with some
additional but comparatively very weak glucocorticoid activity. Relative to cortisol, it is
to 10 times the glucocorticoid potency but 250 to 800 times the mineralocorticoid potency .
Fludrocortisone is added to hydrocortisone to provide additional mineralocorticoid potency.
The rationale for adding mineralocorticoid treatment is that an experimental sepsis study
showed marked nuclear factor NF-κB mediated down regulation of vascular mineralocorticoid
receptors .
Corticosteroids attenuate inflammation in various organs an effect partly related to
inhibition of nuclear factor NF-κB. Improve cardiovascular function by restoring effective
blood volume through increased mineralocorticoid activity and by increasing systemic vascular
resistance through vascular α-Adrenergic responsiveness and reduces inflammation-mediated
vasodilation .
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Completed |
NCT02204852 -
Co-administration of Iloprost and Eptifibatide in Septic Shock Patients
|
Phase 2 | |
Completed |
NCT02079402 -
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
|
Phase 4 |